Asthma and COPD: Interchangeable use of inhalers. A document of Italian Society of Allergy, Asthma and Clinical Immmunology (SIAAIC) & Italian Society of Respiratory Medicine (SIMeR)

Pulmonary Pharmacology and Therapeutics

Volumn 34, Issue , 2015, Pages 25-30

  Lavorini, Federico ^a   Braido, Fulvio ^b   Baiardini, Ilaria ^b   Blasi, Francesco ^c   Canonica, Giorgio Walter ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Adherence; Asthma; COPD; Generics; Inhalers; Switching

Indexed keywords

ANTIASTHMATIC AGENT; RESPIRATORY STIMULANT AGENT; BRONCHODILATING AGENT; GENERIC DRUG;

ASTHMA; BIOEQUIVALENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSULTATION; COST CONTROL; DRUG BIOAVAILABILITY; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; INHALER; MEDICAL SOCIETY; MEDICATION COMPLIANCE; PATIENT EDUCATION; PERSONAL EXPERIENCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; STRUCTURED QUESTIONNAIRE; THERAPEUTIC EQUIVALENCE; ATTITUDE TO HEALTH; DRUG LEGISLATION; DRUG SUBSTITUTION; ECONOMICS; EUROPE; HEALTH PERSONNEL ATTITUDE; NEBULIZER; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ASTHMA; ATTITUDE OF HEALTH PERSONNEL; BRONCHODILATOR AGENTS; COST SAVINGS; DRUG SUBSTITUTION; DRUGS, GENERIC; EUROPE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LEGISLATION, DRUG; MEDICATION ADHERENCE; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84943241713     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2015.07.005     Document Type: Review

References (36)

1. Penning-van Beest F., van Herk-Sukel M., Gale R., Lammers J.W., Herings R. Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis. Respir. Med. 2011 Feb, 105:259-265.
2. Daley-Yates P., Parkins D. Establishing bioequivalence for inhaled drugs; weighing the evidence. Exp. Opin. Drug Deliv. 2011, 8:1297-1308.
3. Price D., Summers M., Zanen P. Could interchangeable use of dry powder inhalers affect patients?. Int. J. Clin. Pract. 2005, 59(Suppl. 149):3-6.
4. Lavorini F., Ninane V., Haughney J., Bjermer L., Molimard M., Dekhuijzen R.P. Switching from branded to generic inhaled medications: potential impact on asthma and COPD. Expert Opin. Drug Deliv. 2013, 10:1597-1602.
5. García-Arieta A., Gordon J. Bioequivalence requirements in the European Union: critical discussion. AAPS 2012, 14:738-748.
6. Evans C., Cipolla D., Chesworth T., et al. Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop report. J. Aerosol Med. Pulm. Drug Deliv. 2012, 25:117-139.
7. Fuglsang A. The US and EU regulatory landscapes for locally acting generic/hybrid inhalation products intended for treatment of asthma and COPD. J. Aerosol Med. Pulm. Drug Deliv. 2012, 25:243-247.
8. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) Including the Requirements for Demonstration of Therapeutic Equivalence between Two Inhaled Products for Use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease 2009, London. (CHMP) CfMPfHU (Ed.).
9. US Food and Drug Administration US FDA Guidance for the In Vitro Portion of Bioequivalence Requirements for Metaproterenol Sulfate and Albuterol Inhalation Aerosol 1989.
10. US Food and Drug Administration US FDA Drug-development Approval Process. Scientific and Regulatory Considerations for Bioequivalence (BE) of Dry Powder Inhalers (DPIs) 2011.
11. (accessed: 1.05.2013). http://www.edctp.org/fileadmin/documents/ethics/Directive_200183EC_of_the_european_parliament.pdf.
12. Adams W.P., Ahrens R.C., Chen M.L., et al. Demonstrating bioequivalence of locally acting orally inhaled drug products (OIPs): workshop summary report. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23:1-29.
13. Lung Alliance Network Correct Use of Inhaled Medication Asthma and COPD 2011, Amersfoort.
14. Buchanan A., Pinnock H., Barnes J. Generic prescribing of breath actuated and dry powder inhalers in the UK. Prim. Care Respir. J. 2002, 11:95.
15. Price D. Do healthcare professionals think that dry powder inhalers can be used interchangeably?. Int. J. Clin. Pract. Suppl. 2005, 149:26-29.
16. Lavorini F., Corrigan C.J., Barnes P.J., et al. Retail sales of inhalation devices in European countries: so much for a global policy. Respir. Med. 2011, 98. 1099-1013.
17. Azouz W., Chrystyn H. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim. Care Respir. J. 2012, 15:208-213.
18. Molimard M., Raherison C., Lignot S., et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J. Aerosol Med. 2003, 16:249-254.
19. Doyle S., Lloyd A., Williams A., Chrystyn H., et al. What happens to patients who have their asthma device switched without their consent?. Prim. Care Respir. J. 2010, 19:131-139.
20. PHARMAC New Zealand Pharmaceutical Schedule Update Effective 1 July 2005 2005, PHARMAC, Wellington.
21. Dockhorn D., Vanden Burgt J., et al. Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma. J. Allergy Clin. Immunol. 1995, 96:50-56.
22. Gillies J., Brown J., Byrnes C., et al. PHARMAC and ventolin in New Zealand. N. Z. Med. 2005, 120:1220.
23. Reti S. Ventolin to Salamol - a crossover study in New Zealand. N. Z. Med. 2006, 119:1-7.
24. Chang C., Cooray M., Mills G., Hancox R. Is Salamol less effective than Ventolin? A randomized, blinded, crossover, study in New Zealand. N. Z. Med. 2007, 120:1267.
25. Thorsson L., Edsbäcker S. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur. Respir. J. 1998, 12:1340-1345.
26. Lavorini F., Levy M., Dekhuijzen P., Crompton G. Inhaler choice and inhalation technique: key factors for asthma control. Prim. Care Respir. J. 2009, 18:241-242.
27. GINA Report, Global strategy for asthma management and prevention, December 2011 update. Available from: http://www.ginasthma.org/.
28. GOLD. Global Strategy for Diagnosis, Management, and Prevention of COPD (2011 Update): Global Initiative for Chronic Obstructive Lung Disease 2011, Available from:. http://www.goldcopd.org/.
29. http://www.worldallergy.org/UserFiles/file/GWCManifestoAdherenceChicago_fullpage.pdf.
30. Braido F., Baiardini I., Blasi F., Pawankar R., Canonica G.W. Adherence to asthma treatments: 'we know, we intend, we advocate'. Curr. Opin. Allergy Clin. Immunol. 2015 Feb, 15:49-55.
31. Thomas M., Price D., Chrystyn H., et al. Inhale corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm. Med. 2009, 9:1.
32. Green M. Compromising Your Drug of Choice: How HMOs are Dictating Your Next Prescription 1996, Public Advocates Office, New York City. http://www.pubadvocate.nyc.gov.
33. Lipton H.L., Kreling D.H., Collins T., Hertz K.C. Pharmacy benefit management companies: dimensions of performance. Annu. Rev. Public Health 1999, 20:361-401.
34. Braido F., Baiardini I., Sumberesi M., Blasi F., Canonica G.W. Obstructive lung diseases and inhaler treatment: results from a national public pragmatic survey. Respir. Res. 2013 Sep 22, 14:94.
35. Booker R. Do patients think that dry powder inhalers can be used interchangeably?. Int. J. Clin. Pract. 2005, 59(Suppl. 149):30-32.
36. Williams A., Chrystyn H. Survey of pharmacists' attitude towards interchangeable use of dry powder inhaler. Pharm. World Sci. 2007, 29:221-227.